论文部分内容阅读
目的探讨黏附分子E-cad、β-cat的表达与非小细胞肺癌临床病理特征及患者预后之间的关系。方法应用免疫组织化学SP法检测53例非小细胞肺癌标本中E-cad、β-cat的表达情况。结果①E-cad及β-cat在高、中分化及低分化的NSCLC组间的表达率差异有显著性(P<0.05)。而E-cad及β-cat的表达与临床分期、组织学类型及淋巴结转移无明显相关性(P均>0.05)。②E-cad与β-cat的表达呈显著性正相关关系(P<0.01)。③E-cad及β-cat正常表达组的平均生存时间显著高于低表达组(P<0.05)。④单因素生存分析显示E-cad、β-cat及临床分期与NSCLC预后有关。⑤多因素生存分析显示:E-cad与临床分期是独立的预后指标(P<0.01)。结论单因素生存分析显示E-cad及β-cat表达缺失者预后不良,多因素生存分析显示E-cad与临床分期是独立的预后指标。E-cad及β-cat共同表达异常者预后更差,联合检测NSCLC中E-can及β-cat的表达,可用于预后评估。
Objective To investigate the relationship between the expression of adhesion molecules E-cad and β-cat and the clinicopathological characteristics and prognosis of non-small cell lung cancer. Methods The expression of E-cad and β-cat in 53 non-small cell lung cancer specimens was detected by immunohistochemical SP method. Results ① The expression rates of E-cad and β-cat in high, moderately differentiated and poorly differentiated NSCLC groups were significantly different (P <0.05). The expression of E-cad and β-cat had no significant correlation with clinical stage, histological type and lymph node metastasis (all P> 0.05). ② The expression of E-cad and β-cat showed a significant positive correlation (P <0.01). ③ The average survival time of E-cad and β-cat normal expression group was significantly higher than that of low expression group (P <0.05). ④ Univariate survival analysis showed that E-cad, β-cat and clinical stage were related to the prognosis of NSCLC. ⑤Multivariate survival analysis showed that E-cad and clinical stage were independent prognostic indicators (P <0.01). Conclusions Univariate survival analysis showed that the prognosis of E-cad and β-cat expression was poor. Multivariate survival analysis showed that E-cad and clinical stage were independent prognostic factors. E-cad and β-cat co-expression of abnormal prognosis worse, combined detection of E-can and β-cat NSCLC expression, can be used for prognosis assessment.